ARQT vs MCK · rev $235.3M vs P/E 20, rev $403.43B
Arcutis Biotherapeutics Inc (ARQT) versus McKesson Corporation (MCK) — a side-by-side from cached financials, not a winner call.
Arcutis Biotherapeutics Inc (ARQT) is a biotechnology company listed on US.
McKesson Corporation (MCK) is a medical distribution company listed on NYSE.
Latest reported ARQT revenue for 2026-06-30 was $235.3M. Net income was $3.7M. ARQT currently screens at market cap $1.64B.
Latest reported MCK revenue for 2026-03-31 was $403.43B. Net income was $4.76B. Revenue was up 12.4% from 2025-03-31 to 2026-03-31. MCK currently screens at market cap $91.30B and trailing P/E 20.3.
ARQT currently screens at market cap $1.64B. MCK currently screens at market cap $91.30B and trailing P/E 20.3.
Not investment advice. Open the ARQT and MCK stock pages for the full models.
Not investment advice.